Breakthrough Medical Vaccine for Glioblastoma (GBM): Personalized Life-Extending Immunotherapy
A new international study introduces an innovative therapeutic option for glioblastoma (GBM) patients: a personalized vaccine based on the genetic analysis of tumor cells, designed to activate the patient’s immune system to specifically attack cancer cells.
This revolutionary approach offers new hope for patients and their families.
Key Findings from the Study:
- The vaccine triggered an immune response in 90% of the patients tested.
- Among patients who responded well to the vaccine, average overall survival increased to 53 months.
- Side effects were generally mild (Grade 1–2).
How Trial-In Pharma Can Help:
Trial-In Pharma assists glioblastoma patients and their families in accessing breakthrough treatments such as this personalized vaccine.
We participate in all clinical meetings with the treating medical team and provide comprehensive professional support throughout the entire process, ensuring that no treatment opportunity is missed.
